Market Research > Industries > Healthcare

Market Research: Rx-to-OTC-Switch Strategies USA

Rx-to-OTC-Switch Strategies USA

Published November 2007

View PDF brochure
View fact sheet

This report provides subscribers with an assessment of success factors for recent switches, the likelihood of future switches, and the likely impact on the OTC market from Rx-to-OTC switches. It offers brand and market projections for new OTC categories and an examination of strategies that OTC marketers can take to defend their brands. The report explores in detail seven brands that have recently made the switch, as well as 20 brands in 8 therapeutic classes that are candidates to switch in the near future. (Y406B)

	ORDER ONLINE

You may submit an online request to subscribe to sections of this report, using a simple three-step process. After submitting your online request, you will then be contacted by a member of our global sales team to confirm the final price, and complete the transaction. Upon acceptance of your order, we will deliver the files in pdf format via email.

STEP 1 of 3

– Select the sections in which you are interested by clicking on the appropriate boxes:

FULL REPORT [US$ 22 300 (twenty two thousand US Dollars)]

INTRODUCTION [US$ 0]

BTC/THIRD CLASS OF DRUGS [US$ 1 100]

Table 3-1 LIST OF SWITCH CANDIDATES THAT COULD BE APPROPRIATE FOR BTC SALE
Table 3-2 SELECTED PRESCRIPTION-ONLY TO PHARMACY SWITCHES IN THE UNITED KINGDOM
Table 3-3 APPLICATIONS TO RECLASSIFY A MEDICINE FILED IN THE UNITED KINGDOM, 2006 TO 2007

RECENT RX-TO-OTC SWITCHES [US$ 9 000]

Table 4-1 RECENT RX-TO-OTC-SWITCH BRANDS ANALYZED IN THIS CHAPTER

Alaway [US$ 1 400]

Table 4A-1 ESTIMATED MANUFACTURERS’ SALES OF NONPRESCRIPTION OCULAR DECONGESTANTS AND ANTIHISTAMINES IN THE UNITED STATES BY BRAND, 2006
Table 4A-2 ESTIMATED MANUFACTURERS’ SALES OF PRESCRIPTION ANTIHISTAMINES IN THE UNITED STATES BY BRAND, 2006 AND 2007
Table 4A-3 ESTIMATED MANUFACTURERS’ SALES OF NONPRESCRIPTION ALLERGY MEDICATIONS IN THE UNITED STATES BY BRAND, 2006
Table 4A-4 U.S. OTC SALES FOR BAUSCH & LOMB, 2001 TO 2006
Table 4A-5 TRACEABLE MEDIA EXPENDITURES FOR OTC OCULAR DECONGESTANTS AND ANTIHISTAMINES IN THE UNITED STATES, 2001 TO 2006

Alli [US$ 1 400]

Table 4B-1 ESTIMATED MANUFACTURERS’ SALES OF RX WEIGHT LOSS MEDICATIONS IN THE UNITED STATES BY BRAND, 2006 AND 2007
Table 4B-2 U.S. OTC SALES FOR GLAXOSMITHKLINE, 2001 TO 2006

Miralax [US$ 1 400]

Table 4C-1 ESTIMATED MANUFACTURERS’ SALES OF MAJOR NONPRESCRIPTION LAXATIVES IN THE UNITED STATES BY BRAND, 2006
Table 4C-2 ESTIMATED MANUFACTURERS’ SALES OF NONPRESCRIPTION LAXATIVES IN THE UNITED STATES, 2006
Table 4C-3 U.S. OTC SALES FOR SCHERING-PLOUGH, 2001 TO 2006
Table 4C-4 TRACEABLE MEDIA EXPENDITURES FOR OTC LAXATIVES IN THE UNITED STATES, 2001 TO 2006

Mucinex [US$ 1 400]

Table 4D-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION COUGH SYRUPS IN THE UNITED STATES, 2004 TO 2006
Table 4D-2 MANUFACTURERS’ SALES OF NONPRESCRIPTION COLD MEDICATIONS IN THE UNITED STATES, 2004 TO 2006
Table 4D-3 TRACEABLE MEDIA EXPENDITURES FOR OTC COLD MEDICATIONS IN THE UNITED STATES, 2001 TO 2006
Table 4D-4 TRACEABLE MEDIA EXPENDITURES FOR OTC COUGH SYRUPS IN THE UNITED STATES, 2001 TO 2006
Table 4D-5 TRACEABLE MEDIA EXPENDITURES FOR MUCINEX IN THE UNITED STATES, 2004 TO 2006
Table 4D-6 MANUFACTURERS’ SALES OF MUCINEX IN THE UNITED STATES, 2004 TO 2007

Plan B [US$ 1 400]

Table 4E-1 MANUFACTURERS’ SALES OF PRESCRIPTION CONTRACEPTIVES IN THE UNITED STATES BY MARKETER, 2006 AND 2007
Table 4E-2 MANUFACTURERS’ SALES OF NONPRESCRIPTION CONTRACEPTIVES IN THE UNITED STATES BY BRAND, 2006
Table 4E-3 TRACEABLE MEDIA EXPENDITURES FOR OTC CONTRACEPTIVES IN THE UNITED STATES, 2001 TO 2006

Prilosec [US$ 1 400]

Table 4F-1 ESTIMATED MANUFACTURERS’ SALES OF PROTON PUMP INHIBITORS IN THE UNITED STATES BY BRAND, 2003 TO 2006
Table 4F-2 ESTIMATED MANUFACTURERS’ SALES OF NONPRESCRIPTION ANTACIDS AND ANTIGAS PRODUCTS IN THE UNITED STATES, 2003 TO 2006
Table 4F-3 U.S. OTC SALES FOR PROCTER & GAMBLE, 2001 TO 2006
Table 4F-4 TRACEABLE MEDIA EXPENDITURES FOR PRILOSEC OTC, 2003 TO 2006
Table 4F-5 TRACEABLE MEDIA EXPENDITURES FOR OTC ANTACIDS AND ANTIGAS PRODUCTS, 2003 TO 2006
Table 4F-6 U.S. OTC SALES FOR PRILOSEC, 2003 TO 2006

Zaditor [US$ 1 400]

Table 4G-1 ESTIMATED MANUFACTURERS’ SALES OF NONPRESCRIP¬TION OCULAR DECONGESTANTS AND ANTIHISTAMINES IN THE UNITED STATES BY BRAND, 2006
Table 4G-2 ESTIMATED MANUFACTURERS’ SALES OF PRESCRIPTION ANTIHISTAMINES IN THE UNITED STATES BY BRAND, 2006 AND 2007
Table 4G-3 ESTIMATED MANUFACTURERS’ SALES OF NONPRESCRIPTION ALLERGY MEDICATIONS IN THE UNITED STATES BY BRAND, 2006
Table 4G-4 U.S. OTC SALES FOR NOVARTIS, 2001 TO 2006
Table 4G-5 TRACEABLE MEDIA EXPENDITURES FOR OTC OCULAR DECONGESTANTS AND ANTIHISTAMINES IN THE UNITED STATES, 2001 TO 2006

POSSIBLE FUTURE RX-TO-OTC SWITCHES [US$ 17 800]

Allergy Relief Products [US$ 5 000]

Table 5A-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION ALLERGY MEDICATIONS IN THE UNITED STATES, 2005 AND 2006
Table 5A-2 ESTIMATED SALES OF PRESCRIPTION LOW/NON-SEDATING ANTIHISTAMINES, 2006 AND 2007
Table 5A-3 ESTIMATED SALES OF PRESCRIPTION INHALED ALLERGY MEDICATIONS, 2006 AND 2007
Figure 5A-1 EXPIRATIONS OF U.S. PATENTS FOR PRESCRIPTION ALLERGY MEDICATIONS
Figure 5A-2 FORECAST SALES OF OTC ALLERGY MEDICATIONS IN THE UNITED STATES, 2006 TO 2012
Table 5A-4 FORECAST SALES OF OTC ALLERGY MEDICATIONS IN THE UNITED STATES, 2006 TO 2012
Figure 5A-3 FORECAST SALES OF RX ALLERGY MEDICATIONS IN THE UNITED STATES, 2006 TO 2012
Table 5A-5 FORECAST SALES OF RX ALLERGY MEDICATIONS IN THE UNITED STATES, 2006 TO 2012

Allegra [US$ 2 000]

Clarinex [US$ 2 000]

Table 5A-6 CHRONOLOGY OF EVENTS IN PETITION TO FORCE LORATADINE TO SWITCH TO OTC STATUS

Zyrtec [US$ 2 000]

Table 5A-7 ZYRTEC’S TRACEABLE MEDIA EXPENDITURES, 2006

Digestives/Proton Pump Inhibitors [US$ 8 400]

Table 5B-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION ANTACIDS AND ANTIGAS PRODUCTS IN THE UNITED STATES, 2006
Figure 5B-1 EXPIRATIONS OF U.S. PATENTS FOR PRESCRIPTION PROTON PUMP INHIBITORS
Figure 5B-2 FORECAST SALES OF OTC ANTACIDS IN THE UNITED STATES, 2006 TO 2012
Table 5B-2 FORECAST SALES OF OTC ANTACIDS IN THE UNITED STATES, 2006 TO 2012
Figure 5B-3 FORECAST SALES OF RX PROTON PUMP INHIBITORS IN THE UNITED STATES, 2006 TO 2012
Table 5B-3 FORECAST SALES OF RX PROTON PUMP INHIBITORS IN THE UNITED STATES, 2006 TO 2012

Aciphex [US$ 2 000]

Nexium [US$ 2 000]

Table 5B-4 NEXIUM’S TRACEABLE MEDIA EXPENDITURES, 2006

Prevacid [US$ 2 000]

Table 5B-5 PREVACID’S TRACEABLE MEDIA EXPENDITURES, 2006

Protonix [US$ 2 000]

Table 5B-6 PROTONIX’S TRACEABLE MEDIA EXPENDITURES, 2006

Zegerid [US$ 2 000]

Erectile Dysfunction Medications [US$ 3 400]

Table 5C-1 ESTIMATED SALES OF PRESCRIPTION ERECTILE DYSFUNCTION DRUGS IN THE UNITED STATES, 2006 AND 2007
Figure 5C-1 EXPIRATIONS OF U.S. PATENTS FOR ERECTILE DYSFUNCTION MEDICATIONS
Figure 5C-2 FORECAST SALES OF PRESCRIPTION ERECTILE DYSFUNCTION MEDICATIONS IN THE UNITED STATES, 2006 TO 2012
Table 5C-2 FORECAST SALES OF PRESCRIPTION ERECTILE DYSFUNCTION MEDICATIONS IN THE UNITED STATES, 2006 TO 2012
Figure 5C-3 FORECAST SALES OF PRESCRIPTION AND NONPRESCRIPTION ERECTILE DYSFUNCTION MEDICATIONS IN THE UNITED STATES, 2010 TO 2012
Table 5C-3 FORECAST SALES OF PRESCRIPTION AND NONPRESCRIPTION ERECTILE DYSFUNCTION MEDICATIONS IN THE UNITED STATES, 2010 TO 2012

Cialis [US$ 2 000]

Table 5C-4 CIALIS’ TRACEABLE MEDIA EXPENDITURES, 2006

Viagra [US$ 2 000]

Table 5C-5 VIAGRA’S TRACEABLE MEDIA EXPENDITURES IN THE UNITED STATES, 2006

Incontinence Medications [US$ 3 400]

Table 5D-1 ESTIMATED SALES OF PRESCRIPTION INCONTINENCE MEDICATIONS IN THE UNITED STATES, 2006 AND 2007
Figure 5D-1 EXPIRATIONS OF U.S. PATENTS FOR PRESCRIPTION INCONTINENCE MEDICATIONS
Figure 5D-2 FORECAST SALES OF PRESCRIPTION INCONTINENCE MEDICATIONS IN THE UNITED STATES, 2006 TO 2012
Table 5D-2 FORECAST SALES OF PRESCRIPTION INCONTINENCE MEDICATIONS IN THE UNITED STATES, 2006 TO 2012
Figure 5D-3 FORECAST SALES OF NONPRESCRIPTION INCONTINENCE MEDICATIONS IN THE UNITED STATES, 2009 TO 2012
Table 5D-3 FORECAST SALES OF NONPRESCRIPTION INCONTINENCE MEDICATIONS IN THE UNITED STATES, 2009 TO 2012

Detrol [US$ 2 000]

Table 5D-4 DETROL’S TRACEABLE MEDIA EXPENDITURES, 2006

Ditropan [US$ 2 000]

Migraine Medications [US$ 2 200]

Table 5E-1 ESTIMATED SALES OF PRESCRIPTION ANTI-MIGRAINE DRUGS IN THE UNITED STATES, 2006 AND 2007
Figure 5E-1 EXPIRATIONS OF U.S. PATENTS FOR ANTI-MIGRAINE DRUGS
Figure 5E-2 FORECAST SALES OF NONPRESCRIPTION PAIN RELIEVERS IN THE UNITED STATES, 2007 TO 2012
Table 5E-2 FORECAST SALES OF NONPRESCRIPTION PAIN RELIEVERS IN THE UNITED STATES, 2007 TO 2012
Figure 5E-3 FORECAST SALES OF PRESCRIPTION PAIN RELIEVERS IN THE UNITED STATES, 2006 TO 2012
Table 5E-3 FORECAST SALES OF PRESCRIPTION PAIN RELIEVERS IN THE UNITED STATES, 2006 TO 2012

Imitrex [US$ 2 000]

Table 5E-4 IMITREX’S TRACEABLE MEDIA EXPENDITURES IN THE UNITED STATES, 2006

Sleeping Aids [US$ 5 000]

Table 5F-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION SLEEPING AIDS IN THE UNITED STATES, 2006
Table 5F-2 ESTIMATED SALES OF PRESCRIPTION SLEEPING AIDS IN THE UNITED STATES, 2006 AND 2007
Figure 5F-1 EXPIRATIONS OF U.S. PATENTS FOR PRESCRIPTION SLEEPING AIDS
Figure 5F-2 FORECAST SALES OF OTC SLEEPING AIDS IN THE UNITED STATES, 2006 TO 2012
Table 5F-3 FORECAST SALES OF OTC SLEEPING AIDS IN THE UNITED STATES, 2006 TO 2012
Figure 5F-3 FORECAST SALES OF PRESCRIPTION SLEEPING AIDS IN THE UNITED STATES, 2006 TO 2012
Table 5F-4 FORECAST SALES OF PRESCRIPTION SLEEPING AIDS IN THE UNITED STATES, 2006 TO 2012
Figure 5F-4 FORECAST SALES OF RX AND OTC SLEEPING AIDS IN THE UNITED STATES, 2010 TO 2012
Table 5F-5 FORECAST SALES OF PRESCRIPTION AND OTC SLEEPING AIDS IN THE UNITED STATES, 2010 TO 2012

Ambien [US$ 2 000]

Table 5F-6 AMBIEN’S TRACEABLE MEDIA EXPENDITURES IN THE UNITED STATES, 2006

Lunesta [US$ 2 000]

Table 5F-7 LUNESTA’S TRACEABLE MEDIA EXPENDITURES IN THE UNITED STATES, 2006

Rozerem [US$ 2 000]

Table 5F-8 ROZEREM’S TRACEABLE MEDIA EXPENDITURES IN THE UNITED STATES, 2006

Smoking Cessation Aids [US$ 1 800]

Table 5G-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION SMOKING CESSATION REMEDIES IN THE UNITED STATES, 2006
Table 5G-2 ESTIMATED SALES OF PRESCRIPTION SMOKING CESSATION AIDS IN THE UNITED STATES, 2006 AND 2007
Figure 5G-1 EXPIRATIONS OF U.S. PATENTS FOR PRESCRIPTION SMOKING CESSATION AIDS
Figure 5G-2 FORECAST SALES OF OTC SMOKING CESSATION AIDS IN THE UNITED STATES, 2006 TO 2012
Table 5G-3 FORECAST SALES OF OTC SMOKING CESSATION AIDS IN THE UNITED STATES, 2006 TO 2012
Figure 5G-3 FORECAST SALES OF RX SMOKING CESSATION AIDS IN THE UNITED STATES, 2006 TO 2012
Table 5G-4 FORECAST SALES OF PRESCRIPTION PAIN RELIEVERS IN THE UNITED STATES, 2006 TO 2012

Zyban [US$ 1 600]

Statins [US$ 5 000]

Table 5H-1 NATIONAL HEART, LUNG, AND BLOOD INSTITUTE’S CHOLESTEROL LEVELS AND RATINGS
Table 5H-2 CLASSES OF CHOLESTEROL REDUCER MEDICATIONS IN THE UNITED STATES AND THEIR EFFECTS ON HIGH BLOOD CHOLESTEROL
Table 5H-3 MANUFACTURERS’ SALES OF LEADING PRESCRIPTION CHOLESTEROL-REDUCING STATINS, 2006 AND 2007
Table 5H-4 ESTIMATED SALES OF SELECT OTC PRODUCTS FOR CHOLESTEROL MAINTENANCE IN THE UNITED STATES, 2005 AND 2006
Figure 5H-1 PATENT EXPIRATIONS OF PRESCRIPTION CHOLESTEROL-REDUCING MEDICATIONS
Figure 5H-2 FIVE-YEAR SALES FORECAST FOR BTC STATINS MARKET, 2007 TO 2012
Table 5H-5 FORECAST SALES OF BTC STATINS IN THE UNITED STATES, 2007 TO 2012
Figure 5H-3 FIVE-YEAR SALES FORECAST FOR OTC STATINS MARKET, 2007 TO 2012
Table 5H-6 FORECAST SALES OF OTC STATINS IN THE UNITED STATES, 2007 TO 2012
Figure 5H-4 FIVE-YEAR SALES FORECAST FOR RX STATINS MARKET, 2007 TO 2012
Table 5H-7 FORECAST SALES OF Rx STATINS IN THE UNITED STATES, 2007 TO 2012

Lipitor [US$ 2 000]

Table 5H-8 DTC SPENDING FOR PRESCRIPTION CHOLESTEROL REDUCING STATINS
Table 5H-9 DIRECT-TO-CONSUMER AD SPEND FOR LIPITOR IN 2006
Figure 5H-5 ANNUAL SALES FORECAST FOR OTC LIPITOR

Mevacor [US$ 2 000]

Table 5H-10 DTC SPENDING FOR PRESCRIPTION CHOLESTEROL-REDUCING STATINS
Figure 5H-6 ANNUAL SALES FORECAST FOR OTC MEVACOR

Pravachol [US$ 2 000]

Table 5H-11 DTC SPENDING FOR PRESCRIPTION CHOLESTEROL-REDUCING STATINS
Figure 5H-7 ANNUAL SALES FORECAST FOR OTC PRAVACHOL

STEP 2 of 3

– Provide your contact information:

All fields in *BOLD are required.

*Name:
*Title:
*Company/Division:
*Address 1 :
Address 2 :
*City:
*State/Province:
*Zip/Postal code:
*Country:
*Phone:
Fax:
*Email:

STEP 3 of 3

– Review and accept our subscription terms and conditions by viewing and clicking below:

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.

Market Research: Rx-to-OTC-Switch Strategies USA

Rx-to-OTC-Switch Strategies USA

ORDER ONLINE

STEP 1 of 3

STEP 2 of 3

STEP 3 of 3

Questions?